From the Editor

Mar 01, 2015
South Africa may have the most developed market for biopharmaceuticals on the African continent, but there are a few critical shortcomings, writes William Looney.
Feb 01, 2015
Pharmaceutical Executive
The small biotech space—credited with ending the drought in new FDA drug approvals in recent years—takes center stage at this year's J.P. Morgan Investors Conference.
Nov 01, 2014
Pharmaceutical Executive
Amid a resurgence in drug development for hard-to-treat conditions, the bigger question is whether the times are as good for the industry tasked with rendering basic science into therapeutically effective medicines.
Aug 01, 2014
Pharmaceutical Executive
Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success, writes William Looney.
Jul 10, 2014
Pharmaceutical Executive
A surprising takeaway from the recent BIO Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.
Jun 09, 2014
Pharmaceutical Executive
Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand, writes William Looney.
May 01, 2014
Pharmaceutical Executive
Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.
Apr 24, 2014
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.
Apr 01, 2014
Pharmaceutical Executive
Three examples from Pharm Exec's coverage this month show that, in our industry, there are always two sides—at least—to every question.
Mar 01, 2014
Pharmaceutical Executive
Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered. A revolution in the making, where legislation combined with market forces as well as community and stakeholder advocacy are adding fresh momentum to a population-based approach to health practice. Population health focuses on a system built around three pillars of care: preventive care, primary care, and coordinated care, all driven by a single performance metric, which is value, as evidenced through quality and outcomes. Executing around this integrative model depends entirely on partnerships, especially with non-traditional players like the physician assistant.
lorem ipsum